Improving Transition of Investigational Medicines in Alzheimer’s Disease From Phase I To Phase II
In January 2012, the Obama administration’s Presidential advisory group outlined an ambitious goal – to prevent and effectively treat Alzheimer’s disease (AD) by 2025, followed by the President signing the National Alzheimer’s Project Act, officially declaring a “War on Alzheimer’s disease”. Stanford Jhee and his team at PAREXEL International discuss how the initiative to increase funding into AD prevention and treatment was driven by the looming AD “epidemic” projected to increase direct costs of AD from $200 billion to $1.1 trillion by 2050.
http://jforcs.com/jcs/wp-content/uploads/2013/02/Improving-Transition-of-Investigational-Medicines-in-Alzheimers-Disease-from-Phase-I-to-Phase-II.pdf